#USA #San Diego #oncology #D3 Bio #KRAS

D3 Bio Showcases Its Innovative KRAS Pipeline at AACR 2026

D3 Bio Inc, a prominent global biotechnology company deeply focused on developing transformative therapies in oncology, is set to spotlight its advances in the field during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. This notable event, which will convene from April 17 to 22 in San Diego, California, is recognized as one of the leading platforms for sharing groundbreaking cancer research.

Presentation Overview

D3 Bio is especially excited to announce that five abstracts have been accepted for presentation at this prestigious conference. Among these, two have been chosen for oral presentations within crucial sessions that focus on clinical trials. This year’s demonstrate a comprehensive insight into D3 Bio's promising pipeline targetting KRAS-driven malignancies, specifically detailing the advancements and ongoing research around several key compounds.

Oral Presentations

The oral presentations will feature:
1. Elisrasib (D3S-001): A next-generation GDP-bound KRAS G12C inhibitor. This presentation titled _“Safety and efficacy of Elisrasib in advanced non-small cell lung cancer previously treated with or without a KRAS G12C inhibitor”_ will be held on Sunday, April 19, 2026, from 1 PM to 3 PM. The study shares results from a phase 1/2 trial and aims to dissect the drug's effectiveness as a monotherapy in difficult-to-treat cases.

2. Combination Therapy Study: _“Safety and efficacy of Elisrasib as monotherapy or in combination with cetuximab in previously treated metastatic colorectal cancer and pancreatic ductal adenocarcinoma”_ will take place on Tuesday, April 21, 2026, from 2:30 PM to 4:30 PM.

Poster Presentations

In addition to the oral sessions, D3 Bio will present three poster sessions that demonstrate their latest findings:
1. D3S-002: A selectively designed ERK1/2 inhibitor. This presentation involves a phase 1 trial of D3S-002 in advanced solid tumors with MAPK mutations.

2. D3S-003: Details on the clinical pharmacokinetic predictions of D3S-003 will also be shared during the conference, further emphasizing the innovative approaches being made toward KRAS inhibition.

3. Finally, further insights into D3S-003 being a dual-state KRAS G12D inhibitor – focusing on the latest experimental results.

Insights from Leadership

George Chen, the Founder, Chairman, and CEO of D3 Bio, expressed enthusiasm about debuting new clinical and preclinical data from the KRAS pipeline. He remarked, _“These presentations will showcase our commitment to advancing transformative therapies for patients with KRAS-driven cancers.”_ The presentations will cater to a diverse audience including oncologists, researchers, and entities invested in cancer therapeutics.

D3 Bio's vision encompasses broadening the understanding and treatment of KRAS mutations, which have been historically challenging in oncology. The company's innovative strategies aim to confront the evolving nature of cancer and provide much-needed solutions in the realm of oncology.

About D3 Bio

D3 Bio is a dedicated global biotechnology enterprise targeting novel oncology and immunology therapies with either first-in-class or best-in-class potential. The firm emphasizes clinical insights and biomarker-driven strategies across various programs that target critical oncogenic drivers. Additionally, D3 Bio retains global rights to all its innovative therapies, reinforcing its commitment to groundbreaking cancer research and treatment.

For more information regarding their KRAS pipeline and ongoing projects, visit their official website at www.d3bio.com.